43024-70-0

Basic information

• Product Name: Ethyl 7-chloropyrazolo[1,5-a]pyrimidine-6-carboxylate
• Synonyms: Ethyl 7-chloropyrazolo[1,5-a]pyrimidine-6-carboxylate;7-Chloropyrazolo[1,5-a]pyrimidine-6-carboxylic acid ethyl ester
• CAS NO: 43024-70-0
• Molecular Formula: C9H8ClN3O2
• Molecular Weight: 225.634
• Product Categories: pyrimidine;Heterocycle-Pyrimidine series
• Mol File: 43024-70-0.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Density: 1.47
• Refractive Index: 1.648
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• CAS DataBase Reference: Ethyl 7-chloropyrazolo[1,5-a]pyrimidine-6-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 7-chloropyrazolo[1,5-a]pyrimidine-6-carboxylate(43024-70-0)
• EPA Substance Registry System: Ethyl 7-chloropyrazolo[1,5-a]pyrimidine-6-carboxylate(43024-70-0)

Safety Data

• Hazardous Substances Data: 43024-70-0(Hazardous Substances Data)

Usage

General Description

Ethyl 7-chloropyrazolo[1,5-a]pyrimidine-6-carboxylate is a chemical compound with a unique structure that includes a pyrazolo ring fused to a pyrimidine ring with a chlorine atom and an ethyl ester group attached. Ethyl 7-chloropyrazolo[1,5-a]pyrimidine-6-carboxylate has potential applications in pharmaceutical research and development, as it may exhibit biological activity and therapeutic properties. Its synthesis and characterization are important for understanding its chemical and physical properties, as well as its potential uses in various fields. As with any chemical compound, proper handling and disposal procedures should be followed to ensure safety and environmental responsibility.

InChI:InChI=1/C9H8ClN3O2/c1-2-15-9(14)6-5-11-7-3-4-12-13(7)8(6)10/h3-5H,2H2,1H3

Upstream product

• 87-13-8 diethyl 2-ethoxymethylenemalonate 
• 29274-17-7 diethyl 2-((1H-pyrazol-5-ylamino)methylene)malonate 
• 43024-61-9 6-ethoxycarbonyl-7-hydroxypyrazolo<1,5-a>pyrimidine 

Downstream Products

• 1333214-16-6 3-(N-tert-butylsulfamoyl)-7-(4-fluoro-2-methylphenylamino)pyrazolo[1,5-a]pyrimidine-6-carboxylic acid 
• 1333213-51-6 N-[7-(4-fluoro-2-methylphenylamino)-6-(4-phenylpiperidine-1-carbonyl)pyrazolo[1,5-a]pyrimidin-3-ylsulfonyl]cyclopropanecarboxamide 
• 1333214-17-7 7-(4-fluoro-2-methylphenylamino)-6-(4-phenylpiperidine-1-carbonyl)pyrazolo[1,5-a]pyrimidine-3-sulfonamide 
• 1333214-15-5 N-tert-butyl-7-(4-fluoro-2-methylphenylamino)-6-(4-phenylpiperidine-1-carbonyl)pyrazolo[1,5-a]pyrimidine-3-sulfonamide 
• 1333214-14-4 ethyl 3-(N-tert-butylsulfamoyl)-7-(4-fluoro-2-methylphenylamino)pyrazolo[1,5-a]pyrimidine-6-carboxylate 
• 1333214-13-3 6-ethoxycarbonyl-7-(4-fluoro-2-methylphenylamino)pyrazolo[1,5-a]pyrimidine-3-sulfonic acid 
• 1333213-67-4 N-[7-(4-fluoro-2-methylphenylamino)-6-(4-phenylpiperidine-1-carbonyl)pyrazolo[1,5-a]pyrimidin-3-ylsulfonyl]acetamide 
• 1333214-12-2 ethyl 7-(4-fluoro-2-methylphenylamino)pyrazolo[1,5-a]pyrimidine-6-carboxylate 
• 1022920-59-7 Pyrazolo[1,5-a]pyrimidine-6-carboxylic acid ethyl ester 
• 43024-89-1 3-bromo-7-(carboxymethyl-amino)-pyrazolo[1,5-a]pyrimidine-6-carboxylic acid ethyl ester 

Relevant articles and documents

CHEMOKINE RECEPTOR ACTIVITY REGULATOR

The invention provides a chemokine receptor activity modulator containing a pyrazolopyrimidine derivative represented by the formula (I) wherein R1, R2, R3, and R4 are as described herein.

3-Aminocarbonyl-substituted fused pyrazolo-derivatives as protein kinase modulators

The present invention relates to pyrazolo[1,5-a]pyrimidine-3-carboxylic acid compounds of formula I or pharmaceutically acceptable salts thereof and their use for the treatment of protein kinase modulation responsive diseases.

Synthesis and Enzymic Activity of 6-Carbethoxy- and 6-Ethoxy-3,7-disubstituted-pyrazolopyrimidines and Related Derivatives as Adenosine Cyclic 3',5'-Phosphate Phosphodiesterase Inhibitors

A number of 3,7-disubstituted 6-carbethoxypyrazolopyrimidines and 3,7-disubstituted 6-ethoxypyrazolopyrimidines have been prepared and evaluated as adenosine cyclic 3',5'-phosphate (cAMP) phosphodiesterase (PDE) inhibitors vs. the low Km enzyme isolated from beef heart, rabbit lung, and kidney preparations.The results were found to be between 0.5 to 13 times as potent as theophylline as inhibitors of PDE, depending on the tissue source.A number of these PDE inhibitors exhibited significant physiological effects in different animal systems, suggesting it should be possible to obtain selective PDE inhibition in various tissues.Several of these heterocycles were found superior to adenosine in inhibiting ADP-induced platelet aggregation in vitro.